JP2017534572A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534572A5
JP2017534572A5 JP2017512313A JP2017512313A JP2017534572A5 JP 2017534572 A5 JP2017534572 A5 JP 2017534572A5 JP 2017512313 A JP2017512313 A JP 2017512313A JP 2017512313 A JP2017512313 A JP 2017512313A JP 2017534572 A5 JP2017534572 A5 JP 2017534572A5
Authority
JP
Japan
Prior art keywords
hydrogen
optionally substituted
group
independently
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534572A (ja
JP6782227B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048640 external-priority patent/WO2016037106A1/en
Publication of JP2017534572A publication Critical patent/JP2017534572A/ja
Publication of JP2017534572A5 publication Critical patent/JP2017534572A5/ja
Priority to JP2020097823A priority Critical patent/JP6918378B2/ja
Application granted granted Critical
Publication of JP6782227B2 publication Critical patent/JP6782227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512313A 2014-09-05 2015-09-04 CaMKII阻害剤及びその使用 Active JP6782227B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020097823A JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046450P 2014-09-05 2014-09-05
US62/046,450 2014-09-05
PCT/US2015/048640 WO2016037106A1 (en) 2014-09-05 2015-09-04 CaMKII INHIBITORS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020097823A Division JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Publications (3)

Publication Number Publication Date
JP2017534572A JP2017534572A (ja) 2017-11-24
JP2017534572A5 true JP2017534572A5 (enExample) 2018-10-11
JP6782227B2 JP6782227B2 (ja) 2020-11-11

Family

ID=54150675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512313A Active JP6782227B2 (ja) 2014-09-05 2015-09-04 CaMKII阻害剤及びその使用
JP2020097823A Expired - Fee Related JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020097823A Expired - Fee Related JP6918378B2 (ja) 2014-09-05 2020-06-04 CaMKII阻害剤及びその使用

Country Status (7)

Country Link
US (2) US10759792B2 (enExample)
EP (1) EP3189052B1 (enExample)
JP (2) JP6782227B2 (enExample)
CN (1) CN107074856A (enExample)
AU (2) AU2015311730A1 (enExample)
CA (1) CA2960101C (enExample)
WO (1) WO2016037106A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US11376302B2 (en) 2017-09-10 2022-07-05 Carmel Haifa University Economic Corporation Ltd. Methods for treating depression and major depressive disorder
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
CA3091789A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
CN113166144A (zh) * 2018-11-27 2021-07-23 豪夫迈·罗氏有限公司 用于治疗和预防细菌感染的芳基化合物
PE20240148A1 (es) * 2020-09-28 2024-02-06 Cardurion Pharmaceuticals Inc COMPUESTOS DE HETEROARILO FUSIONADO Y SU USO COMO INHIBIDORES DE CaMKII

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913124A (en) * 1932-01-02 1933-06-06 American Sundries Co Inc Vaporizer
US2690441A (en) * 1953-06-11 1954-09-28 Searle & Co 3-carboline derivatives
GB1268773A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
BE758991A (fr) * 1969-11-18 1971-05-17 Reeves Bros Inc Procede de reticulation hydrodynamique d'une mousse de polyurethanne
PL80610B1 (enExample) * 1970-03-12 1975-08-30
GB8600651D0 (en) * 1986-01-11 1986-02-19 Beecham Group Plc Compounds
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
ES2178157T3 (es) 1997-01-31 2002-12-16 Univ Leland Stanford Junior Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
EP1439849A4 (en) 2001-10-01 2005-09-28 Univ Vanderbilt USE OF CALMODULIN KINASE II INHIBITORS FOR THE TREATMENT OF MYOCARDIAL FUNCTIONAL DISORDERS IN STRUCTURAL HEART DISEASE
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US20060057639A1 (en) 2004-06-16 2006-03-16 Pitt Geoffrey S CaMKII/calcium channel phosphorylation-related compositions and methods
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
WO2006049215A1 (ja) 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP1896472A1 (de) 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
JP2009500475A (ja) 2005-07-01 2009-01-08 ザ テキサス エイ アンド エム ユニヴァーシティ システム 酸化亜鉛ポリマーナノ複合材料及び酸化亜鉛ポリマーナノ複合材料の製造方法
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
LT2247558T (lt) * 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
CN102131809A (zh) 2008-07-23 2011-07-20 沃泰克斯药物股份有限公司 三环吡唑并吡啶激酶抑制剂
EP2323482A4 (en) 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8907097B2 (en) 2008-10-31 2014-12-09 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Eg5阻害剤
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2758376A4 (en) * 2011-09-19 2015-04-29 Vitas Pharma Res Private Ltd HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS
EA030253B1 (ru) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Азахиназолиновые ингибиторы атипичной протеинкиназы c
AU2014225889B2 (en) 2013-03-06 2018-12-06 The Johns Hopkins University CaMKII inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2016512198A5 (enExample)
EP3490565B1 (en) Azetidine derivatives as chemokine receptor modulators and uses thereof
JP2018522866A5 (enExample)
JP6342805B2 (ja) 置換ピラゾロ[3,4−d]ピリミジンおよびその用途
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2019527682A5 (enExample)
JP2018522867A5 (enExample)
JP2025041790A (ja) ピリダジノン化合物およびその使用
JP2011506588A5 (enExample)
JP2013010792A5 (enExample)
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
JP2019510787A5 (enExample)
JP2017537940A5 (enExample)
JP2017048227A (ja) 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法
JP2015508092A5 (enExample)
JP2021508318A (ja) チューブリン阻害剤
JP2019521964A5 (enExample)
KR20240128987A (ko) Flt3의 억제제로서의 피라진 화합물
JP2022549601A5 (enExample)
JP2022520907A (ja) Nurr1受容体調節因子
KR20140023332A (ko) 티에노〔2,3­d〕피리미딘 유도체 및 부정맥을 치료하기 위한 이의 용도
JP5881864B2 (ja) 炭素環ヌクレオシドならびにその医薬的使用および組成物
JP2017513934A (ja) フェナントロリンホスホン酸誘導体及びその調製方法と応用
JP2017513934A5 (enExample)
CN119350296A (zh) 一类取代的喹啉酮类衍生物及其用途